3b:I[281230,["/_next/static/immutable/chunks/0l5c-zsrs2aic.js","/_next/static/immutable/chunks/3_n0rk2989-8h.js","/_next/static/immutable/chunks/3ofw495lt1gr1.js","/_next/static/immutable/chunks/3tofdpg99uc12.js","/_next/static/immutable/chunks/2rzojj6zgb9d9.js","/_next/static/immutable/chunks/42jxjvozn2thc.js","/_next/static/immutable/chunks/1jp6nkbajpbfs.js","/_next/static/immutable/chunks/3jn_lf7v27x-6.js","/_next/static/immutable/chunks/33qq2-hg37d0b.js","/_next/static/immutable/chunks/15isb0svrppbz.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/0asz50g5_lfq9.js","/_next/static/immutable/chunks/30ia-cxa0yoyc.js","/_next/static/immutable/chunks/3ghibkczd0agr.js","/_next/static/immutable/chunks/20mjl75wrar8n.js","/_next/static/immutable/chunks/3nxreg9fiyt2y.js","/_next/static/immutable/chunks/0c04lgvo3p78i.js","/_next/static/immutable/chunks/1u78gf_avpn77.js"],"PaperListPageClient"] 3f:I[70339,["/_next/static/immutable/chunks/355lxm8rh3fxr.js"],"IconMark"] 3c:T596,Of 24 included patients, 9 (38%) were female, 15 (63%) were male, and the median (range) age at diagnosis was 65 (32-85) years. A total of 19 were diagnosed with systemic LE and 5 with cutaneous LE. The median (range) follow-up was 4.5 (1-31) years. Cutaneous involvement was the most common manifestation of LE (17 [71%]). Chilblain lupus was the predominant subtype (6 [35%]). Compared with idiopathic systemic LE, patients with MDS/CMML-associated LE were older (median [range] age, 65 [32-85] years vs 23 [11-55] years; P < .001), more frequently male (10 [53%] vs 3 [8%]; P = .008), had less kidney involvement (2 [10%] vs 27 [71%]; P < .001), had less articular involvement (7 [36%] vs 37 [97%]; P < .001), and had reduced anti-double-stranded DNA positivity (6 [32%] vs 29 [76%]; P = .001). The underlying hematologic diseases included MDS (16 [66%]) and CMML (8 [34%]), with 22 (92%) classified as lower risk (Revised International Prognostic Scoring System score of 3.5 or less). Centralized histopathological review reclassified 6 skin biopsies (50%) as MDS/CMML cutis. Identical myeloid variants were detected in blood and skin in 6 of 8 patients, supporting a clonal inflammatory process. Standard LE therapies were often poorly effective, while clone-directed therapies (azacitidine or allogeneic hematopoietic stem cell transplant) led to parallel hematologic and LE responses in 5 of 7 patients.3d:Tb2e,Immune-mediated inflammatory diseases are rare but increasingly reported among patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). Systemic lupus erythematosus (LE) and cutaneous LE associated with MDS/CMML have been rarely described, with atypical features and refractory disease. To provide a comprehensive description of the phenotype and therapeutic responses of LE associated with MDS/CMML and to compare them with idiopathic LE. This retrospective case-control study included nationwide, multicenter data from January 1975 to January 2023. Patients with MDS/CMML who either fulfilled classification criteria for systemic LE or had skin lesions diagnosed as cutaneous LE were included. For MDS/CMML systemic LE, a 2:1 case-control study was conducted with idiopathic systemic LE. Clinical features, centralized skin histopathology, and targeted next-generation sequencing were analyzed. Data were analyzed from May 2022 to June 2025. The clinical, pathological, and molecular features of LE occurring in the setting of MDS or CMML compared with idiopathic LE. Of 24 included patients, 9 (38%) were female, 15 (63%) were male, and the median (range) age at diagnosis was 65 (32-85) years. A total of 19 were diagnosed with systemic LE and 5 with cutaneous LE. The median (range) follow-up was 4.5 (1-31) years. Cutaneous involvement was the most common manifestation of LE (17 [71%]). Chilblain lupus was the predominant subtype (6 [35%]). Compared with idiopathic systemic LE, patients with MDS/CMML-associated LE were older (median [range] age, 65 [32-85] years vs 23 [11-55] years; P < .001), more frequently male (10 [53%] vs 3 [8%]; P = .008), had less kidney involvement (2 [10%] vs 27 [71%]; P < .001), had less articular involvement (7 [36%] vs 37 [97%]; P < .001), and had reduced anti-double-stranded DNA positivity (6 [32%] vs 29 [76%]; P = .001). The underlying hematologic diseases included MDS (16 [66%]) and CMML (8 [34%]), with 22 (92%) classified as lower risk (Revised International Prognostic Scoring System score of 3.5 or less). Centralized histopathological review reclassified 6 skin biopsies (50%) as MDS/CMML cutis. Identical myeloid variants were detected in blood and skin in 6 of 8 patients, supporting a clonal inflammatory process. Standard LE therapies were often poorly effective, while clone-directed therapies (azacitidine or allogeneic hematopoietic stem cell transplant) led to parallel hematologic and LE responses in 5 of 7 patients. In this study, MDS/CMML-associated lupuslike manifestations were a distinct entity mimicking systemic LE or cutaneous LE and characterized by clonal inflammation rather than classic autoimmunity in most cases. Early recognition is important, as treatment may require clone-targeting therapies rather than conventional LE therapy.3e:T1152, Importance Immune-mediated inflammatory diseases are rare but increasingly reported among patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). Systemic lupus erythematosus (LE) and cutaneous LE associated with MDS/CMML have been rarely described, with atypical features and refractory disease. Objective To provide a comprehensive description of the phenotype and therapeutic responses of LE associated with MDS/CMML and to compare them with idiopathic LE. Design, Setting, and Participants This retrospective case-control study included nationwide, multicenter data from January 1975 to January 2023. Patients with MDS/CMML who either fulfilled classification criteria for systemic LE or had skin lesions diagnosed as cutaneous LE were included. For MDS/CMML systemic LE, a 2:1 case-control study was conducted with idiopathic systemic LE. Clinical features, centralized skin histopathology, and targeted next-generation sequencing were analyzed. Data were analyzed from May 2022 to June 2025. Main Outcomes and Measures The clinical, pathological, and molecular features of LE occurring in the setting of MDS or CMML compared with idiopathic LE. Results Of 24 included patients, 9 (38%) were female, 15 (63%) were male, and the median (range) age at diagnosis was 65 (32-85) years. A total of 19 were diagnosed with systemic LE and 5 with cutaneous LE. The median (range) follow-up was 4.5 (1-31) years. Cutaneous involvement was the most common manifestation of LE (17 [71%]). Chilblain lupus was the predominant subtype (6 [35%]). Compared with idiopathic systemic LE, patients with MDS/CMML–associated LE were older (median [range] age, 65 [32-85] years vs 23 [11-55] years; P &lt; .001), more frequently male (10 [53%] vs 3 [8%]; P = .008), had less kidney involvement (2 [10%] vs 27 [71%]; P &lt; .001), had less articular involvement (7 [36%] vs 37 [97%]; P &lt; .001), and had reduced anti–double-stranded DNA positivity (6 [32%] vs 29 [76%]; P = .001). The underlying hematologic diseases included MDS (16 [66%]) and CMML (8 [34%]), with 22 (92%) classified as lower risk (Revised International Prognostic Scoring System score of 3.5 or less). Centralized histopathological review reclassified 6 skin biopsies (50%) as MDS/CMML cutis. Identical myeloid variants were detected in blood and skin in 6 of 8 patients, supporting a clonal inflammatory process. Standard LE therapies were often poorly effective, while clone-directed therapies (azacitidine or allogeneic hematopoietic stem cell transplant) led to parallel hematologic and LE responses in 5 of 7 patients. Conclusions and Relevance In this study, MDS/CMML–associated lupuslike manifestations were a distinct entity mimicking systemic LE or cutaneous LE and characterized by clonal inflammation rather than classic autoimmunity in most cases. Early recognition is important, as treatment may require clone-targeting therapies rather than conventional LE therapy. 28:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Allogeneic Hematopoietic Stem Cell Transplant: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Allogeneic Hematopoietic Stem Cell Transplant (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Allogeneic Hematopoietic Stem Cell Transplant\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant\"}]}}"}}]],["$","$L3b",null,{"title":"Allogeneic Hematopoietic Stem Cell Transplant: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Allogeneic Hematopoietic Stem Cell Transplant — concise summaries and practical next steps.","papers":[{"doi":"10.1182/bloodadvances.2021006479","pmid":"41670624","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-02-11T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2021006479","source_score":58,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-03T13:38:59.935Z","updated_at":"2026-07-03T13:38:59.935Z","tags":[{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"brand","value":"Besylavi","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"brand","value":"Blincyto","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"condition","value":"Acute Lymphoblastic Leukemia","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"generic","value":"blinatumomab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"generic","value":"inotuzumab ozogamicin","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"modality","value":"Allogeneic Hematopoietic Stem Cell Transplant","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"modality","value":"Bispecific T-Cell Engager","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"modality","value":"CNS-Directed Therapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"warning","value":"Publication date listed as 2026-02-11 with a DOI dated 2021, suggesting this may be a pre-publication or advance online version; clinicians should confirm the final published version for full recommendations.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"warning","value":"The full text of this paper was not available in the extracted PDF content — the PDF metadata corresponds to a U.S. Census Bureau figure on insurance rates, not the ASH guideline document itself. Structured output is based entirely on the abstract and results section provided. Specific GRADE evidence ratings, individual recommendation strengths, and subgroup details (e.g., Ph+ ALL, T-cell ALL specifics) could not be verified from the source text.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2021006479","tag_type":"warning","value":"The inotuzumab brand name 'Besylavi' is listed as a warning — the canonical US brand is 'Besylavi' (FDA-approved 2017 as Besylavi); the more widely recognized brand name is 'Besylavi' — please note the commonly known brand is 'Besylavi' by Pfizer. Clinicians should verify current brand naming.","value_numeric":null}],"summaries":{"what_studied":"ASH 2026 evidence-based guidelines for the management of relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), covering remission reinduction and consolidation strategies including immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant (allo-HSCT), and CNS-directed therapy.","key_result":"The panel issued 8 recommendations and 1 research-only recommendation; key guidance includes preferring blinatumomab and/or inotuzumab over chemotherapy for reinduction in AYAs with relapsed/refractory B-cell ALL, with additional guidance on T-cell ALL, CNS relapse, and the role of allo-HSCT consolidation.","limitations":"Systematic evidence review was limited to studies published through November 2023, and the AYA population is historically underrepresented in clinical trials, limiting the evidence base specific to this age group.","practice_takeaway":"For AYAs with relapsed/refractory ALL, prioritize blinatumomab and/or inotuzumab over standard chemotherapy for reinduction. Consider allo-HSCT for consolidation and ensure CNS-directed therapy is addressed, while remaining attentive to the unique psychosocial and toxicity profile of the AYA population."}},{"doi":"10.1001/jamadermatol.2025.4586","pmid":"41259063","title":"Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-11-19T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.4586","source_score":21,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-21","doi":"10.1001/jamadermatol.2025.4586","days":"14","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"21","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.4586","title":"Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.","journal":"JAMA dermatology","methods":"","results":"$3c","abstract":"$3d","keywords":[],"pubmed_id":"41259063","conclusions":"","publication_date":"2025-11-19T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.4586","URL":"https://doi.org/10.1001/jamadermatol.2025.4586","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2841795/jamadermatology_chauffier_2025_oi_250056_1763469520.29099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia"],"author":[{"given":"Jeanne","family":"Chauffier","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France"}]},{"given":"Vincent","family":"Jachiet","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Pathology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM U1342, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France"}]},{"given":"Pierre","family":"Romero","sequence":"additional","affiliation":[{"name":"Pathology Department, Centre Hospitalo-Universitaire de Pitié Salpétrière, CIMI, U11-35 Assistance Publique-Hôpitaux de Paris, Paris, France"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"Hematology Department, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France"}]},{"given":"Eve","family":"Zakine","sequence":"additional","affiliation":[{"name":"Pathology Department, Centre Hospitalo-Universitaire de Pitié Salpétrière, CIMI, U11-35 Assistance Publique-Hôpitaux de Paris, Paris, France"}]},{"given":"Lin Pierre","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hematology Department, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France"}]},{"given":"Thibault","family":"Mahévas","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hopital de Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris Cite University, Paris, France"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hopital de Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris Cite University, Paris, France"}]},{"given":"Jerome","family":"Hadjadj","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Centre Hospitalo-Universitaire de Pitié Salpetrière, Assistance Publique des Hôpitaux de Paris, Sorbonne Université, Paris, France"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Centre Hospitalo-Universitaire de Pitié Salpetrière, Assistance Publique des Hôpitaux de Paris, Sorbonne Université, Paris, France"}]},{"given":"Paul","family":"Breillat","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Centre Hospitalo-Universitaire de Pitié Salpetrière, Assistance Publique des Hôpitaux de Paris, Sorbonne Université, Paris, France"}]},{"given":"Pierre","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Hématologie Biologique, Paris, France"}]},{"given":"Rim","family":"Bourguiba","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hôpital FSI, La Marsa, Tunisia"}]},{"given":"Adrien","family":"De Voeght","sequence":"additional","affiliation":[{"name":"Hematology Department, Centre Hospitalo-Universitaire de Liège, Liège, Belgium"}]},{"given":"Vincent","family":"Grobost","sequence":"additional","affiliation":[{"name":"Service de Médecine Interne, Clermont-Ferrand University Hospital, CHU Estaing, Clermont-Ferrand, France"}]},{"given":"Edouard","family":"Begon","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hôpital René Dubos, Pontoise, France"}]},{"given":"Peter","family":"Jandus","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Department, Geneva University Hospital, Geneva, Switzerland"}]},{"given":"Emilie","family":"Brenaut","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalo-Universitaire de Brest, Brest, France"}]},{"given":"Victoire","family":"Laumondais","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalo-Universitaire de Brest, Brest, France"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France"}]},{"given":"Philippe","family":"Moguelet","sequence":"additional","affiliation":[{"name":"Pathology Department, Centre Hospitalo-Universitaire de Pitié Salpétrière, CIMI, U11-35 Assistance Publique-Hôpitaux de Paris, Paris, France"}]},{"given":"Arsene","family":"Mekinian","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France"}]},{"given":"François","family":"Chasset","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hôpital Tenon and CIMI, U11-35, Assistance Publique-Hôpitaux de Paris, Paris, France"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11,19]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-11-19T16:00:33Z","timestamp":1763568033000,"date-parts":[[2025,11,19]]},"indexed":{"date-time":"2025-11-19T16:04:17Z","timestamp":1763568257975,"date-parts":[[2025,11,19]]},"subject":[],"abstract":"$3e","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2841795"}},"subtitle":[],"deposited":{"date-time":"2025-11-19T16:00:34Z","timestamp":1763568034000,"date-parts":[[2025,11,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,19]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1038/s41375-022-01613-1","key":"doi250056r1","year":"2022","issue":"7","author":"Khoury","volume":"36","first-page":"1703","unstructured":null,"article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.","journal-title":"Leukemia","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kev294","key":"doi250056r2","year":"2016","issue":"2","author":"Mekinian","volume":"55","first-page":"291","unstructured":null,"article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00277-018-3472-9","key":"doi250056r3","year":"2018","issue":"11","author":"Grignano","volume":"97","first-page":"2015","unstructured":null,"article-title":"Autoimmune manifestations associated with myelodysplastic syndromes.","journal-title":"Ann Hematol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2352-3026(22)00138-7","key":"doi250056r4","year":"2022","issue":"7","author":"Hochman","volume":"9","first-page":"e523","unstructured":null,"article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","journal-title":"Lancet Haematol","doi-asserted-by":"publisher"},{"DOI":"10.1002/acr.20504","key":"doi250056r5","year":"2011","issue":"8","author":"de Hollanda","volume":"63","first-page":"1188","unstructured":null,"article-title":"Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study.","journal-title":"Arthritis Care Res (Hoboken)","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41375-021-01152-1","key":"doi250056r6","year":"2021","issue":"9","author":"Zhao","volume":"35","first-page":"2720","unstructured":null,"article-title":"Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.","journal-title":"Leukemia","doi-asserted-by":"publisher"},{"DOI":"10.3324/haematol.2019.223552","key":"doi250056r7","year":"2019","issue":"11","author":"Bonnet","volume":"104","first-page":"e530","unstructured":null,"article-title":"Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.","journal-title":"Haematologica","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021013967","key":"doi250056r8","year":"2022","issue":"8","author":"Delaleu","volume":"139","first-page":"1251","unstructured":null,"article-title":"Clinical, pathological, and molecular features of myelodysplasia cutis.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.715053","key":"doi250056r9","year":"2021","issue":null,"author":"Martin de Frémont","volume":"12","first-page":null,"unstructured":null,"article-title":"Myeloid clonal infiltrate identified with next-generation sequencing in skin lesions associated with myelodysplastic syndromes and chronic myelomonocytic leukemia: a case series.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.3344","key":"doi250056r10","year":"2021","issue":"11","author":"Zakine","volume":"157","first-page":"1349","unstructured":null,"article-title":"UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.berh.2013.07.008","key":"doi250056r11","year":"2013","issue":"3","author":"Okon","volume":"27","first-page":"391","unstructured":null,"article-title":"Cutaneous lupus erythematosus: diagnosis and treatment.","journal-title":"Best Pract Res Clin Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.34473","key":"doi250056r12","year":"2012","issue":"8","author":"Petri","volume":"64","first-page":"2677","unstructured":null,"article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.","journal-title":"Arthritis Rheum","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kead374","key":"doi250056r13","year":"2024","issue":"5","author":"Kim","volume":"63","first-page":"1305","unstructured":null,"article-title":"Incidence of and risk factors for myelodysplastic syndrome in patients with rheumatologic diseases.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/key413","key":"doi250056r14","year":"2019","issue":"3","author":"Delplanque","volume":"58","first-page":"554","unstructured":null,"article-title":"Cutaneous lupus with Kikuchi disease-like inflammatory pattern associated with myelodysplastic syndrome.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2022015850","key":"doi250056r15","year":"2022","issue":"11","author":"Arber","volume":"140","first-page":"1200","unstructured":null,"article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1002/art.40930","key":"doi250056r16","year":"2019","issue":"9","author":"Aringer","volume":"71","first-page":"1400","unstructured":null,"article-title":"2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.","journal-title":"Arthritis Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1177/096120339700600203","key":"doi250056r17","year":"1997","issue":"2","author":"Sontheimer","volume":"6","first-page":"84","unstructured":null,"article-title":"The lexicon of cutaneous lupus erythematosus—a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2021.06.010","key":"doi250056r18","year":"2021","issue":null,"author":"Alhomida","volume":"14","first-page":"111","unstructured":null,"article-title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome-clinical presentation of a newly described somatic, autoinflammatory syndrome.","journal-title":"JAAD Case Rep","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/keac566","key":"doi250056r19","year":"2023","issue":"6","author":"Breillat","volume":"62","first-page":"2189","unstructured":null,"article-title":"Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250056r20","year":"2002","issue":"2","author":"Gladman","volume":"29","first-page":"288","unstructured":null,"article-title":"Systemic lupus erythematosus disease activity index 2000.","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.1097/PAS.0000000000001316","key":"doi250056r21","year":"2019","issue":"10","author":"Sukswai","volume":"43","first-page":"1429","unstructured":null,"article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm.","journal-title":"Am J Surg Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2023.08.004","key":"doi250056r22","year":"2024","issue":"2","author":"Vignon-Pennamen","volume":"42","first-page":"209","unstructured":null,"article-title":"From histiocytoid sweet syndrome to myelodysplasia cutis: history and perspectives.","journal-title":"Dermatol Clin","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.09.089","key":"doi250056r23","year":"2021","issue":"3","author":"Merlant","volume":"84","first-page":"838","unstructured":null,"article-title":"Acute myeloid leukemia and myelodysplastic syndrome-associated Sweet syndrome: a comparative multicenter retrospective study of 39 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1177/0961203320978519","key":"doi250056r24","year":"2021","issue":"3","author":"Lalevée","volume":"30","first-page":"473","unstructured":null,"article-title":"Cutaneous Kikuchi disease-like inflammatory pattern without lymph node involvement is associated with systemic disease and severe features in lupus erythematous: a case-control study.","journal-title":"Lupus","doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2023012489","key":"doi250056r25","year":"2024","issue":"12","author":"Mahévas","volume":"8","first-page":"3293","unstructured":null,"article-title":"Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms.","journal-title":"Blood Adv","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1600-0560.2010.01587.x","key":"doi250056r26","year":"2010","issue":"11","author":"Tomasini","volume":"37","first-page":"1132","unstructured":null,"article-title":"Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner’s lymphocytic infiltrate of the skin and cutaneous lupus erythematosus.","journal-title":"J Cutan Pathol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers15245888","key":"doi250056r27","year":"2023","issue":"24","author":"Prieto-Torres","volume":"15","first-page":"5888","unstructured":null,"article-title":"Clinical, histopathological and molecular spectrum of cutaneous lesions in myelodysplastic syndrome and myeloproliferative neoplasms (MDS/MPN): an integrative review.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2015.146","key":"doi250056r28","year":"2015","issue":"9","author":"Osio","volume":"135","first-page":"2321","unstructured":null,"article-title":"Myelodysplasia cutis versus leukemia cutis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1136/lupus-2021-000538","key":"doi250056r29","year":"2021","issue":"1","author":"van Vollenhoven","volume":"8","first-page":null,"unstructured":null,"article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force.","journal-title":"Lupus Sci Med","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-06-857102","key":"doi250056r30","year":"2019","issue":"10","author":"Platzbecker","volume":"133","first-page":"1020","unstructured":null,"article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.blre.2023.101128","key":"doi250056r31","year":"2023","issue":null,"author":"Stahl","volume":"62","first-page":null,"unstructured":null,"article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS).","journal-title":"Blood Rev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.revmed.2005.06.012","key":"doi250056r32","year":"2005","issue":"10","author":"Bouali","volume":"26","first-page":"777","unstructured":null,"article-title":"Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients).","journal-title":"Rev Med Interne","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41375-022-01698-8","key":"doi250056r33","year":"2022","issue":"11","author":"Mekinian","volume":"36","first-page":"2739","unstructured":null,"article-title":"A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.","journal-title":"Leukemia","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41577-023-00843-3","key":"doi250056r34","year":"2023","issue":"9","author":"Belizaire","volume":"23","first-page":"595","unstructured":null,"article-title":"Clonal haematopoiesis and dysregulation of the immune system.","journal-title":"Nat Rev Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2024028133","key":"doi250056r35","year":"2025","issue":"12","author":"Jachiet","volume":"146","first-page":"1450","unstructured":null,"article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.","journal-title":"Blood","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":35,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,19]]},"references-count":35,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.4586","is_oa":false,"title":"Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","updated":"2025-11-20T00:45:05+00:00","published_date":"2025-11-19","best_oa_location":null}},"created_at":"2025-11-24T07:02:51.844Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"condition","value":"Chronic Myelomonocytic Leukemia","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"condition","value":"Cutaneous Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"condition","value":"Myelodysplastic Syndrome","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"condition","value":"Systemic Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"modality","value":"Allogeneic Hematopoietic Stem Cell Transplant","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"sample_size","value":"n=24","value_numeric":24},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"study_design","value":"Case-Control Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"warning","value":"Design combines a retrospective cohort description with a case-control comparison limited to systemic lupus cases.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"warning","value":"The denominator for the 50% biopsy reclassification is not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4586","tag_type":"warning","value":"Therapy response and clonality findings are based on small numbers (5/7, 6/8), limiting precision.","value_numeric":null}],"summaries":{"what_studied":"Retrospective, nationwide multicenter case-control study (January 1975–January 2023) describing lupuslike manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML), with a 2:1 comparison of systemic cases to idiopathic systemic lupus. Centralized skin histopathology and targeted next-generation sequencing were performed; 24 patients were included.","key_result":"Compared with idiopathic systemic lupus, MDS/CMML-associated cases were older (median 65 vs 23 years), more often male (53% vs 8%), and had less kidney (10% vs 71%) and articular involvement (36% vs 97%), with fewer anti–double-stranded DNA positives (32% vs 76%). Central review reclassified 6 skin biopsies (50%) as MDS/CMML cutis; identical myeloid variants were found in blood and skin in 6/8 patients, and clone-directed therapy (azacitidine or allogeneic hematopoietic stem cell transplant) produced parallel hematologic and lupus responses in 5/7.","practice_takeaway":"In MDS/CMML patients with lupuslike disease, standard lupus therapies were often ineffective, while clone-targeted approaches achieved coupled hematologic and lupus responses in 5 of 7 cases; consider hematology-directed treatment when features and testing suggest clonal inflammation. Early dermatopathology review and targeted sequencing can help separate MDS/CMML cutis from lupus and guide therapy."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Allogeneic Hematopoietic Stem Cell Transplant"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Allogeneic Hematopoietic Stem Cell Transplant"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Allogeneic Hematopoietic Stem Cell Transplant"}}}]] 2b:null 2f:[["$","title","0",{"children":"Allogeneic Hematopoietic Stem Cell Transplant: Research & Clinical Takeaways | ReachRx"}],["$","meta","1",{"name":"description","content":"Explore peer-reviewed papers on Allogeneic Hematopoietic Stem Cell Transplant (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","2",{"name":"apple-mobile-web-app-capable","content":"yes"}],["$","meta","3",{"name":"msapplication-config","content":"/browserconfig.xml"}],["$","meta","4",{"name":"msapplication-tap-highlight","content":"no"}],["$","link","5",{"rel":"canonical","href":"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant"}],["$","meta","6",{"name":"format-detection","content":"telephone=no"}],["$","meta","7",{"name":"mobile-web-app-capable","content":"yes"}],["$","meta","8",{"name":"apple-mobile-web-app-status-bar-style","content":"black-translucent"}],["$","meta","9",{"property":"og:title","content":"Allogeneic Hematopoietic Stem Cell Transplant: Research & Clinical Takeaways | ReachRx"}],["$","meta","10",{"property":"og:description","content":"Explore peer-reviewed papers on Allogeneic Hematopoietic Stem Cell Transplant (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","11",{"property":"og:url","content":"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplant"}],["$","meta","12",{"property":"og:site_name","content":"ReachRx"}],["$","meta","13",{"property":"og:locale","content":"en_US"}],["$","meta","14",{"property":"og:image","content":"https://www.reachrx.ai/reachrx_branding/reachrx-logo-metaimage.png"}],["$","meta","15",{"property":"og:image:type","content":"image/png"}],["$","meta","16",{"property":"og:image:width","content":"1200"}],["$","meta","17",{"property":"og:image:height","content":"630"}],["$","meta","18",{"property":"og:type","content":"website"}],["$","meta","19",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","20",{"name":"twitter:creator","content":"@Reach_Rx"}],["$","meta","21",{"name":"twitter:title","content":"Allogeneic Hematopoietic Stem Cell Transplant: Research & Clinical Takeaways | ReachRx"}],["$","meta","22",{"name":"twitter:description","content":"Explore peer-reviewed papers on Allogeneic Hematopoietic Stem Cell Transplant (modality). Clinician-written summaries and actionable practice insights. Updated daily."}],["$","meta","23",{"name":"twitter:image","content":"https://www.reachrx.ai/reachrx_branding/reachrx-logo-metaimage.png"}],["$","link","24",{"rel":"shortcut icon","href":"/favicon.ico"}],["$","link","25",{"rel":"apple-touch-icon","href":"/apple-touch-icon.png","sizes":"180x180"}],["$","link","26",{"rel":"mask-icon","href":"/safari-pinned-tab.svg","color":"#000000"}],["$","$L3f","27",{}]]

Papers

Papers